Devyser Partners with Illumina
Devyser announced a strategic partnership with Illumina that will pair selected Illumina sequencing platforms with Devyser’s proprietary reagent kits. Under the agreement, Devyser’s customers can obtain the sequencers through a reagent‑commitment model rather than a traditional capital purchase. The collaboration leverages Illumina’s hardware leadership and Devyser’s niche assay portfolio to streamline next‑generation sequencing (NGS) workflows for clinical labs. The move signals a shift toward subscription‑style access in the molecular diagnostics market.
Foundation of HER2 Gastric Cancer ASCO/CAP Guidelines—Overview of the Differences Between ASCO-CAP Breast and Gastric Cancer Scoring-January 28, 2026
The on‑demand webinar hosted by CAP TODAY on January 28, 2026, featured Dr. Josef Rüschoff, a leading authority on HER2 testing, to explain the newest ASCO/CAP guidelines for HER2 assessment in gastric cancer. It highlighted why HER2 is a critical therapeutic target beyond breast...
In MS Diagnosis, the Case for Κ-FLC Index
An international expert panel has recommended that the intrathecal kappa free light chain (κ‑FLC) index be added to the next revision of multiple sclerosis (MS) diagnostic criteria as a quantitative, cost‑effective alternative to oligoclonal bands (OCBs). κ‑FLC can be measured...
For Newer Sepsis Diagnostics, What the Studies Show
Newer sepsis diagnostics such as monocyte distribution width (MDW), Intellisep, and MeMed BV are showing promise in early clinical studies but each has distinct limitations. MDW, available on the Beckman Coulter CBC platform, improves sepsis detection when combined with white‑blood‑cell...
What the Evolving Microbial Nomenclature Means for the Clinical Microbiology Lab
Rapid advances in whole‑genome sequencing are prompting frequent revisions to microbial taxonomy and nomenclature, creating operational challenges for clinical microbiology labs. While some updates—such as recognizing Staphylococcus pseudintermedius—enhance antimicrobial‑resistance insight and enable species‑specific susceptibility breakpoints, other changes driven mainly by...
Reaching for Workflow Efficiencies in Urinalysis
A CAP TODAY roundtable examined how artificial intelligence can streamline urinalysis workflow, particularly through AI‑driven reflex testing that merges urine chemistry and microscopy results with electronic health‑record data. Participants from Sysmex America and Beckman Coulter noted that adoption has been gradual...
Agilent Launches S540MD Slide Scanner System
Agilent Technologies introduced the S540MD slide scanner, a whole‑slide imaging system now on sale in select European markets. The scanner holds up to 540 slides, supports continuous loading, standard rack compatibility, automated scanning modes, and AI‑assisted tissue detection. It is...
IDT Unveils NGS Portfolio
Integrated DNA Technologies (IDT) announced a new next‑generation sequencing (NGS) portfolio that includes the DNA EZ v2 library preparation kit, the xGen Exome v2 Hyb spike‑in panel, a 1,536‑member set of full‑length unique dual‑index adapters, and an upgraded whole‑genome sequencing system. The suite targets...
Illumina Launches Software for Multiomic Analysis
Illumina unveiled Illumina Connected Multiomics, a cloud‑based platform that unifies single‑cell, spatial transcriptomics, proteomics, and methylation data for large‑scale analysis. The system aggregates thousands of samples from Illumina and third‑party assays, delivering reproducible results through DRAGEN secondary analysis. AI‑driven tools...
FDA Clears Cepheid Xpert GI Multiplex PCR Test
Cepheid’s Xpert GI panel received FDA clearance, offering a multiplex PCR test that identifies 11 bacterial, viral, and parasitic gastrointestinal pathogens from a single stool sample. The assay delivers results in roughly 74 minutes and operates on the existing GeneXpert...
FDA Clears Copan PhenoMatrix Software
The U.S. Food and Drug Administration granted 510(k) clearance to Copan Group’s PhenoMatrix, an AI‑driven image‑assessment tool that runs on the WASPLab automation platform. Classified as a class II device, the software automatically sorts and evaluates bacterial culture plate images across...
Proscia Earns Top Score in KLAS Digital Pathology Report
Proscia topped the KLAS Research Digital Pathology 2026 report with a 95.2 overall performance score, the highest among U.S. vendors. The company earned A+ and A grades across six customer‑experience categories, and every surveyed client said they plan to keep...
ARUP Creates Innovation Central Laboratory
ARUP Laboratories has unveiled the Innovation Central Laboratory, a dedicated hub for co‑development with pharmaceutical and biotech partners. The facility is designed to validate technologies and move next‑generation diagnostics from concept through to commercial readiness. It will host projects ranging...
Exa Capital Acquires Health Care Workforce Platform StaffReady
Exa Capital has acquired StaffReady, a SaaS platform that manages clinical workforces across hospitals, labs, and pharmaceutical testing firms. The platform streamlines staff scheduling, compliance, and inspection readiness, helping health‑care organizations reduce operational bottlenecks. StaffReady will remain independent with its...
Copan’s PhenoMatrix Software Gets FDA 510(k) Clearance
Copan Group’s PhenoMatrix software, an AI‑driven image assessment tool for bacterial culture plates, received FDA 510(k) clearance as a Class II in‑vitro diagnostic device. The clearance covers analysis of blood, chocolate, MacConkey and ChroMagar agar plates, enabling semi‑quantitative colony counting and...
